Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
The currently used 2008 World Health Organization classification recognizes two types of systemic anaplastic large T cell lymphoma according to ALK protein expression in tumour cells. First, the 'anaplastic large cell lymphoma, ALK positive' (ALK(+) ALCL) that is characterized by the presence of ALK gene rearrangements and consequent ALK protein expression, and, second, the 'anaplastic large cell lymphoma, ALK negative' (ALK(-) ALCL) that is a provisional entity lacking ALK protein expression but cannot be distinguished morphologically from ALK(+) ALCL. In this review we summarize the current knowledge on the genetic lesions and biological features that underlie the pathogenesis of ALK(+) and the ALK(-) ALCL and that can lead to the use of targeted anti-cancer agents.
['Boi|Michela|M|', 'Zucca|Emanuele|E|', 'Inghirami|Giorgio|G|', 'Bertoni|Francesco|F|']
D000077548:Anaplastic Lymphoma Kinase D000970:Antineoplastic Agents D000077547:Crizotinib D006801:Humans D016130:Immunophenotyping D017728:Lymphoma, Large-Cell, Anaplastic D058990:Molecular Targeted Therapy D047428:Protein Kinase Inhibitors D011720:Pyrazoles D011725:Pyridines D020794:Receptor Protein-Tyrosine Kinases D015398:Signal Transduction D014178:Translocation, Genetic
lymphoma Crizotinib JAK PRDM1 anaplastic lymphoma kinase